Anti-Toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro

被引：27

作者：

Derouin, F ^{[1
]}

Santillana-Hayat, M ^{[1
]}

机构：

[1] Hop St Louis, Lab Parasitol Mycol, Fac Med, F-75006 Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 09期

关键词：

D O I：

10.1128/AAC.44.9.2575-2577.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The anti-Toxoplasma activities of nine antiretroviral drugs were examined in vitro. Nucleoside analogs had no effect on parasite growth, whereas ritonavir and nelfinavir were inhibitory for Toxoplasma, with 50% inhibitory concentrations of 5.4 and 4.0 mu g/ml, respectively. None of the antiviral drugs affected the anti-Toxoplasma activity of pyrimethamine or sulfadiazine.

引用

页码：2575 / 2577

页数：3

共 12 条

[1] In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii [J].

Atzori, C ;

Angeli, E ;

Mainini, A ;

Agostoni, F ;

Micheli, V ;

Cargnel, A .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1629-1634

[2] In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors [J].

Cassone, A ;

De Bernardis, F ;

Torosantucci, A ;

Tacconelli, E ;

Tumbarello, M ;

Cauda, R .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :448-453

[3] Serine protease inhibitors block invasion of host cells by Toxoplasma gondii [J].

Conseil, V ;

Soête, M ;

Dubremetz, JF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1358-1361

[4] INVITRO EFFECTS OF FOLATE INHIBITORS ON TOXOPLASMA-GONDII [J].

DEROUIN, F ;

CHASTANG, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1753-1759

[5] HIV-protease inhibitors [J].

Flexner, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1281-1292

[6] ZIDOVUDINE ANTAGONIZES THE ACTION OF PYRIMETHAMINE IN EXPERIMENTAL-INFECTION WITH TOXOPLASMA-GONDII [J].

ISRAELSKI, DM ;

TOM, C ;

REMINGTON, JS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (01) :30-34

[7] TOXOPLASMIC ENCEPHALITIS IN AIDS [J].

LUFT, BJ ;

REMINGTON, JS .

CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :211-222

[8] 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus [J].

Masur, H ;

Kaplan, JE ;

Holmes, KK ;

Alston, BL ;

Ampel, N ;

Anderson, JR ;

Baker, AC ;

Barr, D ;

Bartlett, JG ;

Bennett, JE ;

Benson, CA ;

Bozzette, SA ;

Chaisson, RE ;

Crumpacker, CS ;

Currier, JS ;

Deyton, L ;

Drew, WL ;

Duncan, WR ;

Eisinger, RW ;

El-Sadr, W ;

Feinberg, J ;

Freedberg, KA ;

Furrer, H ;

Gnann, JW ;

Goldberger, MJ ;

Goldie, S ;

Goosby, EP ;

Gross, PA ;

Hafner, R ;

Havlir, D ;

Hooton, TM ;

Jabs, DA ;

Jacobson, MA ;

Janoff, E ;

Kitahata, M ;

Kovacs, JV ;

Leport, C ;

Levin, MJ ;

Lopez, JC ;

Marco, M ;

Mayers, DL ;

Melnick, DA ;

Mofenson, LM ;

Montaner, JSG ;

Moore, R ;

Neaton, J ;

Nelson, C ;

O'Neill, JF ;

Palefsky, J ;

Pau, A .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (11) :873-908

[9] Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients [J].

Merry, C ;

Barry, MG ;

Mulcahy, F ;

Ryan, M ;

Heavey, J ;

Tjia, JF ;

Gibbons, SE ;

Breckenridge, AM ;

Back, DJ .

AIDS, 1997, 11 (04) :F29-F33

[10] Nelfinavir mesylate: A protease inhibitor [J].

Pai, VB ;

Nahata, MC .

ANNALS OF PHARMACOTHERAPY, 1999, 33 (03) :325-339

← 1 2 →